Prediction of Therapeutic Response and Prognosis in Ovarian Cancer Patients With Plasma Circulating Biomarkers
Cancer Innovation · 2025-08 · 4 (4)
DOI: 10.1002/cai2.70014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Innovation, online erschienen am 04.06.2025. Verfasst von Haixia Cheng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Cell and Molecular Biology & State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for C…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chinese Academy of Medical Sciences.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
To assess whether changes in TP53 mutations and copy number alterations (CNA) in plasma circulating tumor DNA (ctDNA) can predict treatment response and prognosis in platinum‐resistant recurrent ovarian cancer (PROC) patients.
Methods
Fifty‐seven PROC patients were recruited. Forty‐three patients with matched tumor and plasma samples were analyzed via both a tumor‐informed ctDNA assay (TICA) and a tumor‐uninformed ctDNA assay (TUCA) profiling TP53 mutations and CNA. The TUCA algorithm was optimized based on TICA results. Fourteen patients without matched tumor tissues were used just for TUCA analysis.
Results
A ctDNA decrease of ≥ 80% from baseline or ctDNA negativity during treatment detected by the TICA (defined as favorable TICA changes) strategy before the third cycle predicted the best overall response, with 81.8% sensitivity and 84.6% specificity. The TUCA strategy was defined as a combination of TP53 mutations and CNA changes. A favorable TUCA change before the third cycle predicted the best overall response, with 90.0% sensitivity and 63.2% specificity. In 12 patients without clinical benefit, the median lead time to detect drug resistance from TUCA to the Response Evaluation Criteria in Solid Tumors was 86.0 days. Patients with favorable ctDNA changes ( n = 15) detected by TUCA before the third cycle had a median progression‐free survival of 9.2 months, versus 3.6 months in those without ( n = 34) (HR: 2.88; 95% CI 1.56–5.30; log‐rank p = 0.0008).
Conclusions
Similar to TICA, ctDNA changes detected by TUCA combined with TP53 mutations and CNA could predict treatment response and prognosis in PROC patients without requiring tumor tissues.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Cell and Molecular Biology & State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking…
- Department of Gynecologic Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.
- Peking University Cancer Hospital Yunnan Hospital/Yunnan Provincial Cancer Hospital/The Third Affiliated Hospital of Kunming Medical University Kunming Yunnan China.
ORCID-Profile: Mei Liu
Förderung
- Chinese Academy of Medical Sciences
Zitieren
APA
Cheng, H., Yuan, G., Liang, L., Wang, T., Zhu, J., Yang, H., Zhou, Z., Wang, P., Song, Q., Jiao, Y., Liu, M., & Wu, L. (2025). Prediction of Therapeutic Response and Prognosis in Ovarian Cancer Patients With Plasma Circulating Biomarkers. Cancer Innovation, 4(4). https://doi.org/10.1002/cai2.70014
Vancouver
Cheng H, Yuan G, Liang L, Wang T, Zhu J, Yang H, et al. Prediction of Therapeutic Response and Prognosis in Ovarian Cancer Patients With Plasma Circulating Biomarkers. Cancer Innovation. 2025;4(4). doi:10.1002/cai2.70014
BibTeX
@article{Cheng2025,
author = {Cheng, Haixia and Yuan, Guangwen and Liang, Leilei and Wang, Tiantian and Zhu, Jiarun and Yang, Hongying and Zhou, Zhendiao and Wang, Pei and Song, Qianqian and Jiao, Yuchen and Liu, Mei and Wu, Lingying},
title = {Prediction of Therapeutic Response and Prognosis in Ovarian Cancer Patients With Plasma Circulating Biomarkers},
journal = {Cancer Innovation},
year = {2025},
volume = {4},
number = {4},
doi = {10.1002/cai2.70014}
}
EUVIMED